Jenoptik AG JEN.DE
Composite 52/100; the shares have moved about 54% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 25/100 — a moderate mark against it.
Balance-sheet strength ranks 74/100 — a moderate point in its favour. Momentum ranks 65/100 — a moderate point in its favour. Valuation ranks 56/100 — a slight point in its favour.
Growth ranks 25/100 — a moderate mark against it. Quality ranks 42/100 — a slight mark against it. Income ranks 49/100 — a slight mark against it.
What the company does Jenoptik AG provides advanced photonic and smart mobility solutions across four segments: Semiconductor & Advanced Manufacturing, Biophotonics, Metrology & Production Solutions, and Smart Mobility Solutions. Its portfolio includes imaging systems, laser technologies, optics, and optoelectronic components used in industrial, medical, and automotive applications.
Key financials Jenoptik reports gross margins of 33.2% and net margins of 7.6%, with revenue down -1.0% but EPS up 81.3%. ROE is 7.9%, ROA 4.6%, and ROCE 8.6%. Debt/Equity stands at 0.38, with a current ratio of 2.29 and interest coverage of 5.67.
Stock health Momentum is strong over 6m (47.79%) and 12m (82.87%), though RSI(14) is 29.90 (oversold). The stock is -27.96% below its 52-week high. Sideravia scores Valuation at 50.5 and Momentum at 67.0, indicating average quality with positive momentum.
Price vs fair value The stock trades at a PREMIUM of 63.60% versus our fair-value estimate of 12.71 and at a discount of 28.12% versus the analyst 12-month target of 44.69. - Forward P/E of 16.26 (vs. trailing 27.35) suggests earnings recovery is priced in (Valuation data). - Net margins at 7.6% lag peers, limiting premium justifications (Key Financials). - Strong 12m momentum (82.87%) may support the premium despite valuation gaps (Momentum data). - Analyst count of 8.0 supports the 44.69 target, implying upside potential (Analyst View).
Looking forward Forward PEG of 0.24 implies undervaluation relative to growth, but high premium vs fair value warrants caution. Focus on margin expansion and execution in core photonic segments to validate the premium.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.